Across TCGA pan-cancer cohorts, SH3GLB1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SH3GLB1 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SH3GLB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH3GLB1 expression acts as an unfavorable survival marker.
LUSC are the cancer types where SH3GLB1 Mutation most reproducibly stratifies survival.